Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy
January 28, 2021 07:00 ET | Source: Trevena Inc. Trevena Inc.
Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection regardless of age or body mass index, in exploratory analysis
CHESTERBROOK, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE)
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of a new analysis of respiratory safety data from the OLINVYK Phase 3 multi-site “real world” safety study in
Pain and Therapy.
The publication is titled, “Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgica
Marek-brzezinski
Trevena-inc
University-of-california-san-francisco
Nasdaq
Opioid-induced-respiratory-depression-observed
Oliceridine-regardless
Body-mass-index
Exploratory-analysis
Label-trial
Postsurgical-pain
Clinical-anesthesia